Microba Life Sciences Ltd (MAP) - Total Liabilities
Based on the latest financial reports, Microba Life Sciences Ltd (MAP) has total liabilities worth AU$12.27 Million AUD (≈ $8.68 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MAP financial resilience to evaluate the company's liquid asset resilience ratio.
Microba Life Sciences Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Microba Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Microba Life Sciences Ltd.
Microba Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Microba Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LS telcom AG
XETRA:LSX
|
Germany | €23.97 Million |
|
Minho M Bhd
KLSE:5576
|
Malaysia | RM66.84 Million |
|
Pudjiadi & Sons Tbk
JK:PNSE
|
Indonesia | Rp155.87 Billion |
|
AB Electrolux (publ)
ST:ELUX-A
|
Sweden | Skr105.92 Billion |
|
Ginegar
TA:GNGR
|
Israel | ILA460.96 Million |
|
Grand House Mulia Pt
JK:HOMI
|
Indonesia | Rp47.63 Billion |
|
Avensia publ AB
ST:AVEN
|
Sweden | Skr155.11 Million |
|
Camino Minerals Corporation
V:COR
|
Canada | CA$4.13 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Microba Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Microba Life Sciences Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.53 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Microba Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual total liabilities of Microba Life Sciences Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$14.94 Million ≈ $10.57 Million |
-11.18% |
| 2023-12-31 | AU$16.82 Million ≈ $11.90 Million |
+104.46% |
| 2022-12-31 | AU$8.23 Million ≈ $5.82 Million |
+38.46% |
| 2021-12-31 | AU$5.94 Million ≈ $4.21 Million |
+67.33% |
| 2020-12-31 | AU$3.55 Million ≈ $2.51 Million |
+14.42% |
| 2019-12-31 | AU$3.10 Million ≈ $2.20 Million |
+116.39% |
| 2018-12-31 | AU$1.43 Million ≈ $1.01 Million |
-- |
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more